Silverarc Capital Management LLC Trims Stake in Geron Co. (NASDAQ:GERN)

Silverarc Capital Management LLC decreased its holdings in shares of Geron Co. (NASDAQ:GERN - Free Report) by 48.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 920,022 shares of the biopharmaceutical company's stock after selling 881,539 shares during the period. Silverarc Capital Management LLC owned approximately 0.15% of Geron worth $3,257,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Harvest Investment Services LLC purchased a new stake in shares of Geron in the fourth quarter valued at about $61,000. Diadema Partners LP purchased a new stake in Geron in the 4th quarter valued at about $708,000. Hsbc Holdings PLC lifted its position in shares of Geron by 378.2% during the 4th quarter. Hsbc Holdings PLC now owns 285,047 shares of the biopharmaceutical company's stock worth $1,008,000 after buying an additional 225,441 shares in the last quarter. Stifel Financial Corp boosted its stake in shares of Geron by 29.9% in the 4th quarter. Stifel Financial Corp now owns 61,658 shares of the biopharmaceutical company's stock worth $218,000 after buying an additional 14,181 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Geron by 1,216.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 131,956 shares of the biopharmaceutical company's stock valued at $467,000 after acquiring an additional 121,929 shares during the last quarter. 73.71% of the stock is owned by institutional investors.

Geron Stock Performance

Shares of NASDAQ GERN remained flat at $1.42 during mid-day trading on Friday. The stock had a trading volume of 6,357,119 shares, compared to its average volume of 11,506,865. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. Geron Co. has a one year low of $1.17 and a one year high of $5.34. The firm has a market capitalization of $904.42 million, a P/E ratio of -4.44 and a beta of 0.66. The business's 50-day simple moving average is $1.64 and its 200-day simple moving average is $2.92.

Geron (NASDAQ:GERN - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million. As a group, equities research analysts forecast that Geron Co. will post -0.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GERN shares. Barclays reiterated an "overweight" rating and set a $4.00 target price (down from $9.00) on shares of Geron in a research note on Thursday, February 27th. B. Riley cut shares of Geron from a "buy" rating to a "neutral" rating and dropped their target price for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. Stifel Nicolaus decreased their price target on shares of Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and issued a $5.00 price target on shares of Geron in a report on Wednesday, March 12th. Finally, Scotiabank reduced their price objective on Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Geron has a consensus rating of "Moderate Buy" and a consensus price target of $5.75.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.